IL -18 is a novel cytokine that induces interferon ( IFN ) -secretion and plays an important role in antitumor immunity. In the present study, we constructed plasmid vectors encoding the murine mature IL -18 cDNA linked with the Ig leader sequence and the pro -IL -18 cDNA to estimate the efficacy of the mature IL -18 vector and to evaluate IL -18 ± producing tumor cells as a tumor vaccine. Colon 26 cells were transfected with the abovementioned vectors or with vector alone ( mock ) . Reverse transcription -polymerase chain reaction analysis showed increased expression of murine IL -18 cDNA in both mature IL -18 and pro -IL -18 transfectants in comparison to that in mock transfected cells. The ability of the culture supernatants of mature IL -18 transfectants to induce IFNsecretion was extremely high ( 40 ± 140 pg / 10 6 cells ) in comparison to that of pro -IL -18 transfectants ( 4 ± 18 pg / 10 6 cells ) . When injected into syngeneic BALB / c mice, the growth of mature IL -18 transfectants, but not pro -IL -18 transfectants, was significantly less than that in mock transfected cells ( P < .01, by ANOVA and analysis of covariance ) . In addition, injection of colon 26 or Meth -A cells into mice immunized with a mature IL -18 transfectant revealed acquired immunity. Depletion of natural killer cells did not affect the growth of transfectants. However, the growth inhibitory effects were partially abrogated following treatment with anti -CD4 + and anti -CD8 + antibodies. These data suggest that the rejection of mature IL -18 / colon 26 cells was mediated through T -cell activation. Gene therapy using mature IL -18 transfectants containing a plasmid vector and the Ig leader sequence may be a useful tumor vaccine. Cancer Gene Therapy ( 2001 ) 8, 9 ± 16
I nterleukin -18 (IL -18) is a novel cytokine identified as interferon -±inducing factor (IGIF ) .
1 Recent studies have shown that IL -18 stimulates T-cell proliferation, augments natural killer ( NK ) cell lytic activity, and induces interferon -( IFN -) production in type 1 T-helper (Th1 ) cells. 2 ± 7 It has also been found that IL-18 selectively enhances Fas ligand -mediated cytotoxicity of cloned murine Th1 cells, but not Th0 or Th2 cells. 3 Micallef et al 8 demonstrated the efficacy of recombinant IL -18 administered intraperitoneally ( i.p. ) or intravenously (i.v.) as a modulator in antitumor immunity. Thus, local IL -18 production is likely to increase antitumor activity of host immune cells via altered IFN -levels. IL -18, like IL -1, lacks a typical leader sequence. 9 IL -18 is processed into the mature active form by caspase-1, which is an IL -1 ± converting enzyme (ICE ) . 10 ICE's homolog caspase-3 or -4 cleaved pro -IL -18 at a different site and the resulting polypeptides had little IFN -±inducing activity. 9, 11, 12 Because of the difficulty in engineering secreted active IL-18, there have been few studies of gene therapy using IL-18. 13 In the present study, we constructed plasmid encoding the murine mature or pro -IL -18 cDNA, and then estimated the efficacy of mature IL -18 ± producing tumor cells as a tumor vaccine. This is the first study to examine the efficacy of the Ig leader sequence to stimulate secretion of active IL -18 by cells transfected with plasmid vectors and the possible use of mature IL -18 ± producing tumor cells as cancer vaccines.
MATERIALS AND METHODS

Reverse transcription -polymerase chain reaction
RNA isolation and reverse transcription -polymerase chain reaction ( RT-PCR ) were carried out as described previously with some modifications.
14 Briefly, cells ( 5Â10 6 ) were lysed in 1 mL of TRIzol reagent (Life Technologies, Grand Island, NY ) , and total cellular RNA was isolated according to the manufacturer's instructions. One microliter of total RNA was added to 19 L of RT-mixture (Takara, Ohtsu, Japan ). After mixing, the samples were incubated at 308C for 10 minutes, 558C for 30 minutes, 958C for 5 minutes, and 48C for at least 5 minutes. PCR -mix ( 80 L ) (Takara ) containing 100 nM primers was added to the RT reactions. PCR cycling parameters were denaturation at 948C for 1 minute, annealing at 608C for 1 minute, and extension at 728C for 1.5 minutes. PCR amplification for murine mature IL -18 cDNA, murine pro -IL-18 cDNA, and -actin were performed for 28, 28, and 24 cycles, respectively. The primer sequences were murine pro -IL - 18 H (down ). The PCR products were separated onto 1% agarose gels and visualized by staining with ethidium bromide. The expected sizes of the PCR products were 595 bp for pro -IL -18, 492 bp for mature IL-18, 775 bp for genomic IL -18, and 1224 bp for -actin.
Murine pro -IL -18 cDNA expression vector
A murine IL -18 cDNA was isolated by RT-PCR using total RNA purified from lipopolysaccharide -stimulated murine spleen cells. The PCR fragment was cloned into the EcoRI /SalI site of pGEM -4Z (Promega, Madison, WI ), and the nucleotide sequence was confirmed by sequence analysis. The same fragment was then subcloned into the EcoRI /SalI site of the pCl -neo plasmid ( Promega ) ( Fig 1A ) .
Murine mature IL -18 cDNA expression vector
A mature IL -18 cDNA molecule was isolated by PCR using the pro -IL -18 cDNA expression vector as a template. The PCR fragment was cloned into a HindIII / XhoI site of the pSecTag2B eukaryotic expression vector, which contains the Ig leader sequence ( Invitrogen, San Diego, CA ) ( Fig 1B ) . The nucleotide sequence was confirmed by sequence analysis using the T7 promoter.
Tumor cells and transfection
Colon 26 cells, which are murine colon adenocarcinoma cells derived from BALB /c mice, 15 were maintained in RPMI 1640 ( Gibco BRL, Grand Island, NY ) medium supplemented with 10% heat -inactivated fetal calf serum, 100 U / mL penicillin G, and 100 g /mL streptomycin. Subconfluent cultures in 100-mm Petri dishes were transfected with 5 g of murine pro -or mature IL -18 expression plasmid or vector alone using the Lipofectamine reagent ( Life Technologies ) according to the manufacturer's instructions. G418 (100 g/mL ) (Life Technologies ) , which selects for the pCl -neo vector, and Zeocin ( 100 g /mL ) , which selects for the pSecTag2B vector, were added to the cells 48 hours later. G418 -or Zeocin -resistant clones were isolated and expanded in culture medium containing 100 g/ mL of G418 or Zeocin.
Bioassay for IL -18 produced from transfectants
The activity of IL -18 produced by colon 26 transfectants was assessed by the cells' abilities to induce IFN -secretion from murine splenocytes according to a previously described method with some modifications. 1 Briefly, flat -bottom 96-well microtiter plates were coated with anti -CD3 monoclonal antibody (Cedarlane Laboratories, Ontario, Canada ) at a concentration of 5 g /mL for 3 hours at 378C and then washed three times with phosphate -buffered saline (PBS, Life Technologies ) . Murine spleen cells (4Â10 3 cells /well ) were incubated with various concentrations of culture supernatants from various transfectants with or without antimouse IL -18 monoclonal antibody (MBL, Nagoya, Japan ) and with 2 -mercaptoethanol (final concentration 5Â10 À 5 M ). After a 24 -hour incubation, IFN -levels were measured using an enzyme -linked immunosorbent assay ( ELISA ) (BioSource, Camarillo, CA ) . For each assay, a standard curve using recombinant cytokine was constructed, and each sample assayed in duplicate. The lower limit of the detection of IFN -was <1 pg /mL.
Animal studies
Seven -week -old female BALB /c and BALB /c nu/nu mice were purchased from Japan SCL (Hamamatsu, Japan ) . Mice were inoculated with freshly prepared suspensions of tumor cells at a concentration of 2Â10 6 cells /mL. Animals were inoculated with a total of 2Â10 5 cells. All were inoculated subcutaneously ( s.c. ) in the right lower abdominal quadrant with a 27-gauge needle. Tumor volumes were measured in mm 3 with a vernier caliper and calculated according to the following formula: aÂb Meth -A cells, of a methylcholanthrene -induced fibrosarcoma of BALB /c origin, 16 were also injected into both nonimmunized and immunized mice.
In vivo depletion of NK cells, CD4
+ , and CD8 + T cells
To deplete NK cells, mice were injected with tumors cells as described above, except that 200 mL of a 1:15 dilution of anti -asialo GM1 antibody ( Wako, Osaka, Japan ) in PBS or control rabbit serum ( diluted 1:15 in PBS ) was injected i.p. into mice 2 days before the tumor challenge and 1 and 3 days after tumor challenge. Similar concentrations of anti -asialo GM1 antibody have been used in vivo to abrogate NK cell activity. 8 Monoclonal antibodies against CD4 + cells (GK 1.5) and CD8 + cells ( 2.43) ( all purchased from American Tissue Culture Collection, Rockville, MD ) or HBSS ( Gibco BRL ) only ( control ) were prepared and injected i.p. (1.0 mg ) into mice ( n= 10 ) to deplete subsets of immune cells 3 days before and once a week after the inoculation of tumor as previously described. 17 Flow cytometric analysis was performed using an EPICS XL (Beckman Coulter, Fullerton, CA ) verifying 95% depletion of specific cell subsets in the spleen after the administration of depleting antibodies ( data not shown ). The tumor volume was recorded.
Histologic evaluation for immune cells infiltrating into tumor tissues
On days 7 and 14 after inoculation, tumors were dissected, fixed in 10% neutral buffered formalin, and embedded in paraffin. Sections (4 m ) were stained with hematoxylin and eosin. For immunohistochemical staining, tissues were embedded in OCT compound (Ames Division, Miles Laboratories, Elkart, IN ) , snap -frozen in liquid nitrogen, and stored at À 808C. Acetone-fixed 6-mm cryostat sections were blocked with goat serum and then immunostained with optimal dilution of the following rat mAbs: L3 / T4 (CD4: Becton Dickinson, Franklin Lakes, NJ ) , KT15 ( CD8: Serotec, Sapporo, Japan ). The slides were then sequentially incubated with biotinylated goat antimouse Igs ( Zymed Laboratories, South San Francisco, CA ) and ABComplex ( Dako, Tokyo, Japan ). Each incubation step lasted at least 30 minutes and was followed by a 10 -minute PBS wash. Sections were then incubated with 0.03% H 2 O 2 and 0.06% 3,3-diaminobenzidine for 2 ±5 minutes, washed in tap water, and counterstained in hematoxylin.
Analysis of the expression MHC class I and class II, B7.1, and B7.2 on tumor cells
Transfectants and parental cells were incubated with FITCconjugated H -2Kd and I -Ad (Pharmingen ), CD80, and CD86 ( Immunotech, Marseille, France ), or IgG2a and IgG2b (Pharmingen ) for 30 minutes. Cells were washed three times and resuspended in CellFIX 2 (Becton Dickinson, Erembodegem -Aaist, Belgium ) . Analysis was performed on an EPICS XL flow cytometer.
Statistical analysis
Statistical analysis was performed by one -way analysis of variance ( ANOVA ) and analysis of covariance. A P value of 0.01 was considered statistically significant. Results are presented as mean standard error (SE ) .
RESULTS
Expression of IL -18 mRNA in transfectants
Seven independent G -418 ±resistant pro -IL -18 clones (pro 1 to 7) and eight independent Zeocin resistant colonies of mature IL -18 transfectants ( mature 1 to 8 ) were isolated and expanded. RNA was isolated, and RT-PCR was performed. Six of seven clones expressing pro -IL -18 mRNA and seven of eight clones expressing mature IL -18 mRNA were YOSHIMURA, HAZAMA, IIZUKA, ET AL: MATURE-IL-18 GENE TRANSFER REDUCES TUMORIGENECITY IN VIVO selected for bioassay (Fig 2 ) . Endogenous IL-18 mRNA was not detected in either colon 26 cells transfected with vector alone ( mock 1 and 2) or in untransfected colon 26 cells (data not shown) .
Bioassay for IL -18 produced from transfectants
Biologic activities of IL -18 produced by colon 26 transfectants were measured by their ability to induce IFN -secretion from murine splenocytes. The levels of IFN -induction by the culture supernatants were between 4 and 18 pg/ mL in the pro -IL-18 transfectants ( 10 6 cells/24 hours ) , between 40 and 140 pg/ mL in the mature IL -18 transfectants, and from 2 to 4 pg /mL in parent cell and vector-alone transfectants (Fig 3 ) . We selected mature 2 (IFN -low-inducing clone; 40 pg /mL ), mature 6 (IFN-high -inducing clone; 140 pg/ mL ) , and pro 2 ( pro -IL -18 /colon 26; 10 pg /mL ) for further examination. The production of IL -18 by the transfectants was stable for more than 6 months, and production fluctuated < 15% in each clone. The bioactivity of each culture supernatant was neutralized by preincubation with antimouse IL-18 antibody at a concentration of 5 g/mL (data not shown) .
Inhibition of tumor growth in vivo
The transfection of pro -or mature IL -18, mock 1 or parental cells did not alter the growth properties of colon 26 cells in vitro as assessed by doubling time or morphology (data not shown ). The tumorigenicities of pro 2, mature 2, mature 6, and mock 1 cultures were examined by s.c. injections into BALB / c mice in three independent experiments. The mean tumor volumes of both the mature 2 and mature 6 clones were significantly reduced (n = 10) , whereas mock 1 grew progressively until the animals died (n =10 ). The mean tumor volumes of both the mature 2 and mature 6 clones were also significantly reduced compared with pro 2 ( Fig 4 ) . Mature 6 was rejected in 7 of 10 mice, mature 2 in 4 of 10, and pro 2 in 3 of 10. The same kind of results were obtained even using other cell lines that induced the same amount of IFN -( data not shown ).
Rechallenge with parental cell ( colon 26 ) and Meth -A
We next examined whether primary rejection of IL-18 transfectants led to protective immunity. Forty days after the disappearance of the initial mature IL-18/ colon 26 implants, seven immunized mice were injected with 2Â10 5 parental colon 26 cells in the lower left abdominal flank. Seven nonimmunized mice were injected in the same manner as control. In all immunized mice, tumors were rejected, whereas nonimmunized mice grew progressively until the animals died (Fig 5) . To demonstrate the specificity of the protective immunity, Meth -A cells were injected into both Figure 3 . Induction of IFN -secretion by culture supernatants from tumor cells. Levels of IFN -secreted from murine splenocytes were measured by ELISA. The levels of IFN -induction by the culture supernatants in the pro -IL -18 transfectants ( pro 1 to 5 ) ( 10 6 cells / 24 hours ) were between 4 and 18 pg / mL, whereas those levels in the mature IL -18 transfectants ( mature 2, 4, 5, 6, 7 ) were between 40 and 140 pg / mL, and those levels in parent cells ( P ) and mock ( 1 to 2 ) showed low levels of from 2 to 4 pg / mL. The fluctuations of this production at different times were < 15% in each clone. Figure 4 . Tumorigenicity of the pro 2, mature 2, mature 6, and mock 1 clones were examined by subcutaneous injection into BALB / c mice in three independent experiments. Mean tumor volume of both mature 2 and mature 6 clones were significantly smaller ( n = 10 ) , whereas clone mock 1 grew progressively until it caused the death of the animals ( n = 10 ) ( P < .01 ) . Tumor volumes are mean SE. nonimmunized (n = 7) and immunized (n =7 ) mice. There was no significant difference in the growth of implanted Meth -A cells between nonimmunized mice and immunized mice (Fig 6 ) .
Effect of anti -asialo GM1, anti -CD4
+ , and anti -CD8 + antibodies on the growth of mature IL -18 transfectants Depleted mice and control mice were inoculated with mature 6 cells. There was no difference in tumor growth between the NK -depleted group (n = 10) and the control group (n =10). Tumors in mice treated either with anti -CD4 + ( n=10) or anti -CD8 + ( n= 10 ) antibodies grew rapidly when compared with those in mice treated with HBSS (control ) ( P<.01) ( Fig 7 ) .
Histology at the site of tumor cell injection
To characterize the host cellular responses augmented by IL -18 production, histological analysis of the injection site was performed 14 days following the injection of tumor cells. In BALB / c mice, massive infiltration of mononuclear cells, but not polymorphonuclear cells, was noted on day 14 after injection of mature IL -18 /colon 26 cells (Fig 8A ) . In contrast, in the case of mock 1, few mononuclear infiltrates were observed (Fig 8B ) . Infiltration of mononuclear cells at the tumor site was also observed at 7 days after injection in mice challenged with the parental cells (colon 26 ) ( Fig  8C ) . Immunohistochemical analysis of tumor implantation sites in BALB /c mice 14 days after s.c. injection of mature 6 transfectant cells revealed a sparse infiltration of CD4 + T cells ( Fig 8D ) and a dense infiltration of CD8 + T cells ( Fig  8E ) in the tumor.
Expression of MHC class I, MHC class II, B7.1, and B7.2 on tumor cells Cells expressing MHC class I and class II, B7.1, and B7.2 were analyzed using flow cytometry. All cells expressed MHC class I, but, MHC class II, B7.1, and B7.2 were not detected on any cells. There was no difference between transfectants and parental cells (data not shown ) .
DISCUSSION
We constructed mature IL -18 expression vectors with the Ig leader sequence and pro -IL -18 cDNA introducing vector. Colon 26 cells were transfected with these vectors. Injection of transfectants into syngeneic mice revealed that the mature 6 clone, which secreted large amount of bioactive IL -18, had the highest rejection rate compared with other transfectants. The rejection response was characterized by sparse infiltration by CD4 + T cells, and massive infiltration by CD8 + T cells. The antitumor effects of IL-18 were partially abrogated following treatment with anti -CD4 + or anti -CD8 + antibodies but not by depletion of NK cells. All immunized mice rejected parental cells but not Meth -A cells in the rechallenge study.
IL -18 stimulates T-cell proliferation, augments NK cell activity, 2, 3, 5, 7 and enhances Fas ligand-mediated cytotoxicity.
3 IL -18 also exhibits significant antitumor effects in BALB /c mice challenged i.p. with syngeneic Meth -A sarcoma cells. 8 Thus, a gene therapy for cancer using IL-18 may be effective through up-regulation of antitumor activities of host immune cells. Only two studies of IL-18 gene therapy for cancer have been reported. Pro-IL-18 transfection into Lewis lung carcinoma cells reduced tumorigenicity to some degree in vivo.
18 Direct injection of a mature IL -18 adenoviral vector into mice with MCA205 elicited an effective immune response. 13 However, a vaccination study using IL -18 cDNA transfectants has not been reported yet.
IL -18, which is related structurally to IL -1, is first synthesized as a leaderless precursor, and it requires ICE for cleavage into an active molecule. For gene therapy, a conventional signal sequence is necessary for extracellular secretion of mature IL -18. In fact, our preliminary study demonstrated that pro -IL -18 cDNA transfectants of Meth -A cells, which is a highly immunogenic tumor, Figure 6 . To demonstrate the specificity of the protective immunity, Meth -A cells were injected into both nonimmunized ( n = 7 ) and immunized ( n = 7 ) mice. There was no significant difference in the growth of implanted Meth -A cells between the two groups. Tumor volumes are mean. Tumor volumes are mean SE. were rejected in all mice (unpublished data ), whereas pro -IL -18 cDNA transfectants of colon 26 cells ( pro 2) , which is a weakly immunogenic tumor failed to show such antitumor effects ( Fig 3 ) . We therefore constructed a mature IL -18 expression vector that contains the Ig leader sequence, and transfected it into colon 26 cells. Secretion of bioactive IL -18 by mature IL -18 transfectants was significantly higher than that by pro -IL -18 cDNA transfectants. Furthermore, the mature IL -18 transfectants were rejected more strongly than pro -IL -18 transfectants.
The levels of secretion of bioactive IL-18 should be important. It has been reported that the dose of IL -18 administered correlates well with the resulting level of serum IFN -and the strength of its antitumor activity. 19 Therefore, for an effective gene therapy it is essential to construct a vector that secretes high levels of bioactive IL -18. Indeed, the abilities of our mature IL -18 transfectant to induce IFN -secretion were well correlated with the rate of the complete rejection. Osaki et al 13 constructed an adenoviral vector that contains the mature IL -18 sequence and the leader sequence of the human parathyroid hormone ( PTH ) gene. The transfectants in the study induced secretion of about 40 pg/mL of IFN -. We constructed a clone using a new vector that contains the Ig leader sequence and induces secretion of large amounts of IFN -( 140 pg /mL ). This result suggests that the Ig leader sequence may be more suitable to induce secretion of IFN -than that of PTH. Because a plasmid vector is easy and relatively safely to handle, it is not necessary to set up an antiviral unit or to worry about toxic viral infection.
Different mechanisms have been demonstrated in cells transfected with different cytokines. IFN -, IL -2, IL -6, IL -12, and IL -15 transfectants induce primarily specific CTL activity, 20 ± 22 whereas TNF -, IL-4, MIP-1, and IL-8 transfectants induce nonspecific antitumor activity and granulocyte infiltration. 20, 23 It is known that tumor rejection induced by local secretion of cytokines is mediated by a dual mechanism involving specific and nonspecific antitumor effectors. With regard to the specific effects, our results indicate that in vivo IL-18 stimulates the sensitization of memory T lymphocytes, which are responsible for specific long -lasting antitumor protection. BALB /c mice, which rejected IL-18/ colon 26 cells, were protected against parental colon 26 tumors, but not against Meth -A tumors. There was no difference in tumor growth between the NKdepleted group and the control group. Tumors in mice treated either with anti -CD4 + (n =10) or anti -CD8 + (n =10) antibodies grew rapidly when compared with those in mice treated with HBSS (control ) (P < .01) (Fig 7) . These results suggest that the main effector cells are T cells, but not NK cells. However, these results are not consistent with results from recombinant IL-18 i.v. studies and IL-18 gene therapy studies using MCA205. 8, 13, 19 Although the reason for the differences was unclear, we thought that secreted bioactive IL -18 at the tumor sites may induce T-cell ± mediated antitumor host reactions. Our data also showed that IL -18 transfectants induced successfully IFN -production. Several studies have demonstrated the efficacy of cancer vaccines using IFN -±producing tumor cells. 24 ± 26 It is unknown whether IL -18 gene therapy is better than IFNgene therapy. Because there is a variety of tumors, it may be important to create a variety of gene therapies. We therefore think that IL -18 gene therapy may be one of the effective strategies for cancer therapy.
In conclusion, our study demonstrates that a mature IL -18 expression vector with the Ig leader sequence is useful for construction of clones that secrete a high amount of bioactive IL -18 and that IL -18 secreting tumor cells can elicit a specific antitumor immune response. Mature IL -18 ±secret-ing tumor cells may be useful as vaccines for cancer therapy.
